

CITATION REPORT

List of articles citing

Hemodynamic effects of sildenafil in men with severe coronary artery disease

DOI: 10.1056/nejm200006013422201

New England Journal of Medicine, 2000, 342, 1622-6.

Source: <https://exaly.com/paper-pdf/31839399/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
297	Safety of sildenafil. 2000 , 10, 613-5		2
296	Medical therapy of unstable angina and non-Q-wave myocardial infarction. 2000 , 86, 24J-33J; discussion 33J-34J		11
295	Acuut myocardinfarct als gevolg van combinatie van sildenafil, nitroglycerine sildenafil, myocardinfarct sildenafil sildenafil met nitroglycerine. 2000 , 38, 205-205		
294	Erectile dysfunction, sildenafil and cardiovascular risk. 2000 , 173, 446-446		
293	Sympathetic activation by sildenafil. <i>Circulation</i> , 2000 , 102, 3068-73	16.7	101
292	Low-power laser irradiation increases cyclic GMP synthesis in penile smooth muscle cells in vitro. 2000 , 18, 291-4		3
291	Sex and the patient with cardiovascular risk factors: focus on sildenafil. <i>American Journal of Medicine</i> , 2000 , 109 Suppl 9A, 13S-21S; discussion 29S-30S	2.4	32
290	Sildenafil has no direct adverse cardiovascular effects. 2000 , &NA;; 20		
289	Diltiazem and mibefradil alter the pharmacokinetics of oral methylprednisolone. 2000 , &NA;; 3		
288	Sleep-disordered breathing and hypertension. <i>New England Journal of Medicine</i> , 2000 , 343, 967	59.2	14
287	Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. 2001 , 37, 286-92		39
286	Sildenafil citrate: a therapeutic update. 2001 , 23, 2-23		65
285	Oral drug therapy for erectile dysfunction. 2001 , 28, 321-34		71
284	Disfunci3 sexual en la hipertensi3 y beneficios del tratamiento con sildenafilo. 2001 , 18, 59-62		
283	Cost-Effectiveness of Sildenafil. 2001 , 134, 250		
282	Cost-effectiveness of sildenafil. 2001 , 134, 249; author reply 250-1		
281	Serum homocysteine and stroke in atrial fibrillation. 2001 , 134, 253-4		13

280 Cost-effectiveness of sildenafil. **2001**, 134, 249-50; author reply 250-1

279 The informationist. **2001**, 134, 251; author reply 252-3 6

278 Celecoxib-induced cholestatic hepatitis. **2001**, 134, 254 41

277 The informationist. **2001**, 134, 251; author reply 252-3 7

276 The informationist. **2001**, 134, 252-3 4

275 Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents. **2001**, 11, 625-30 2

274 Current World Literature. **2001**, 11, 637-656

273 Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications. **2001**, 19, 40-5 15

272 Editor's comment on: "Press release: further research supports Viagra safety profile". **2001**, 87, 905-7; author reply 907-9

271 The efficacy of sildenafil in different etiologies of erectile dysfunction. *International Urology and Nephrology*, **2001**, 32, 403-7 2,3 12

270 The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. **2001**, 70, 270-9 49

269 Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. **2001**, 15, 707-13 77

268 Sex, the heart, and sildenafil. **2001**, 26, 388-415 4

267 What's new in urology. **2001**, 193, 179-201 1

266 Updating erectile dysfunction. **2001**, 1, 143-145

265 [Interaction between sildenafil and antihypertensive drugs: what is evidence-based?]. **2001**, 126, 1144-9 7

264 Erectile dysfunction. **2001**, 86, 2391-4 23

263 Cardiovascular safety of sildenafil. **2002**, 13, 439-43 0

262	Interaction of sildenafil with cAMP-mediated vasodilation in vivo. 2002 , 40, 763-7		24
261	Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. 2002 , 25, 1336-9		207
260	Overview of the cardiovascular effects of tadalafil. <i>European Heart Journal Supplements</i> , 2002 , 4, H32-H47		63
259	Sildenafil reverses O ₂ constriction of the rabbit ductus arteriosus by inhibiting type 5 phosphodiesterase and activating BK(Ca) channels. 2002 , 52, 19-24		36
258	Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. <i>International Journal of Impotence Research</i> , 2002 , 14, 38-43	2.3	34
257	Safe sex for men with coronary artery disease: exercise, sildenafil, and risk of cardiac events. 2002 , 287, 766-7		8
256	Cardiovascular safety in erectile dysfunction treatment. 2002 , 2, 301-304		5
255	Pharmacological aspects of erectile dysfunction. 2002 , 89, 101-12		14
254	Phosphodiesterase type 5 inhibition in cardiovascular disease: experimental models and potential clinical applications. <i>European Heart Journal Supplements</i> , 2002 , 4, H19-H23	1.5	8
253	Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. 2002 , 287, 719-25		132
252	Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. <i>Circulation</i> , 2002 , 105, 2398-403	16.7	508
251	The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. 2002 , 40, 1232-40		238
250	Management of Erectile Dysfunction. 2002 , 10, 431-452		5
249	[Efficacy and safety of sildenafil in patients with erectile dysfunction and hypertension. Prognostic factors]. <i>Medicina Clínica</i> , 2002 , 119, 281-5	1	4
248	Vasoprotection by nitric oxide: mechanisms and therapeutic potential. <i>Cardiovascular Research</i> , 2002 , 55, 250-60	9.9	231
247	Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. 2002 , 59, 747-52		58
246	A 4-year update on the safety of sildenafil citrate (Viagra). 2002 , 60, 67-90		188
245	Relaxation and cGMP formation in response to sildenafil and sodium nitroprusside in saphenous veins from normotensive and hypertensive patients. <i>American Journal of Hypertension</i> , 2002 , 15, 798-802 ^{2,3}		5

244	Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. 2002 , 86, 131-41		64
243	Fatal overdosage with sildenafil citrate (Viagra): first report and review of the literature. 2002 , 21, 623-9		21
242	Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. 2002 , 90, 677-80		135
241	Lifestyle changes in New Yorkers after September 11, 2001 (data from the Post-Disaster Heart Attack Prevention Program). 2002 , 90, 680-2		15
240	[Cardio-vascular effects of sildenafil: new data]. 2002 , 51, 341-5		3
239	Etiology and treatment of erectile failure in diabetes mellitus. 2002 , 2, 501-9		44
238	Clinical update on sildenafil citrate. 2002 , 53, 219-23		10
237	Sildenafil citrate: lessons learned from 3 years of clinical experience. <i>International Journal of Impotence Research</i> , 2002 , 14 Suppl 1, S43-52	2.3	59
236	Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. <i>International Journal of Impotence Research</i> , 2002 , 14, 178-88	2.3	25
235	Tolerability and safety profile of sildenafil citrate (Viagra) in Latin American patient populations. <i>International Journal of Impotence Research</i> , 2002 , 14 Suppl 2, S54-9	2.3	8
234	The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. 2003 , 8, 5-21		51
233	Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. 2003 , 4, 457-65		69
232	Erectile dysfunction in the cardiac patient. 2003 , 4, 466-71		16
231	Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. 2003 , 4, 488-96		31
230	Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. <i>European Urology</i> , 2003 , 43, 544-51	10.2	12
229	Sildenafil in patients with cardiovascular disease. 2003 , 92, 26M-36M		32
228	Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. 2003 , 9, 9-15		27
227	Coronary artery flow reserve in diabetics with erectile dysfunction using sildenafil. 2003 , 2, 8		5

226	Oral drug treatment of erectile dysfunction. <i>International Journal of Impotence Research</i> , 2003 , 15 Suppl 7, S27-9	2.3	1
225	Effects of sildenafil on cardiopulmonary responses during stress. 2003 , 169, 1417-21		6
224	Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. 2003 , 78, 1207-13		91
223	Disfunci3n er3ctil: abordaje y tratamiento integral desde atenci3n primaria. 2003 , 10, 471-483		
222	Cardiovascular safety of sildenafil. 2003 , 26, 453-60		14
221	Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. 2003 , 24, 2206-12		55
220	Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. <i>Circulation</i> , 2003 , 108, 239-44	16.7	124
219	Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. 2003 , 101, 265-9		111
218	Should the patient with coronary artery disease use sildenafil?. 2003 , 6, 161-5		11
217	Sildenafil in erectile dysfunction: a critical review. 2003 , 19, 241-62		77
216	Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction. 2003 , 28, 291-7		4
215	[Sex, erectile dysfunction, and the heart: a growing problem]. 2003 , 28, 284-90		20
214	Hemodynamic effects of sildenafil in patients with stable ischemic heart disease. 2003 , 90, 153-7		13
213	Vascular effects of sildenafil in hypertensive cardiac transplant recipients. <i>American Journal of Hypertension</i> , 2003 , 16, 874-7	2.3	26
212	Long-term use of sildenafil. <i>Expert Opinion on Pharmacotherapy</i> , 2003 , 4, 397-405	4	89
211	Sildenafil citrate does not affect cardiac contractility in human or dog heart. 2003 , 19, 747-52		59
210	Effect of sildenafil on arterial stiffness and wave reflection. 2003 , 8, 243-8		67
209	[Sildenafil does not change coronary flow reserve in diabetics with erectile dysfunction]. 2003 , 128, 190-5		5

208	Erectile dysfunctions. 2003 , 2, 350-6		2
207	Evaluation of the effects of sildenafil citrate (Viagra) on canine renal artery, carotid and aortic blood flow with the aid of color Doppler sonography. 2003 , 71, 103-7		8
206	MenB Health Study: epidemiology of erectile dysfunction and cardiovascular disease. <i>Circulation Journal</i> , 2003 , 67, 656-9	2.9	44
205	Heart Disease and Erectile Dysfunction. 2004 ,		
204	Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. 2004 , 164, 514-20		65
203	A 66-year-old man with sexual dysfunction. 2004 , 291, 2994-3003		19
202	The Role of the NO Axis and its Therapeutic Implications in Pulmonary Arterial Hypertension. 2004 , 213-229		
201	Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. 2004 , 93, 796-801		36
200	Erectile dysfunction in heart disease patients. <i>International Journal of Impotence Research</i> , 2004 , 16 Suppl 2, S13-7	2.3	12
199	Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5). <i>International Journal of Impotence Research</i> , 2004 , 16, 412-7	2.3	12
198	Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. 2004 , 93, 147-53		80
197	Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient. 2004 , 23, 125-9		14
196	Erectile dysfunction in the cardiac patient. 2004 , 30, 50-4		6
195	Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure. 2004 , 76, 371-8		30
194	The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. 2004 , 44, 2339-48		180
193	Treatment of erectile dysfunction in patients with cardiovascular disease : guide to drug selection. 2004 , 64, 1533-45		15
192	New treatment options for erectile dysfunction in patients with diabetes mellitus. 2004 , 64, 2667-88		69
191	Sildenafil. 2004 ,		

190	Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. <i>American Journal of Hypertension</i> , 2004 , 17, 1040-4	2.3	38
189	Sildenafil: emerging cardiovascular indications. 2004 , 78, 1496-506		53
188	Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. <i>Circulation</i> , 2004 , 110, 3149-55	16.7	143
187	The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. 2005 , 128, 3065-73		31
186	Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. <i>Circulation</i> , 2005 , 112, 2980-5	16.7	260
185	Effects of sildenafil on myocardial blood flow in humans with ischemic heart disease. 2005 , 16, 443-9		17
184	Past, present, and future: a 7-year update of Viagra (sildenafil citrate). 2005 , 59, 680-91		61
183	Erectile dysfunction in patients with coronary artery disease. <i>International Journal of Impotence Research</i> , 2005 , 17, 209-15	2.3	19
182	A case of erectile dysfunction and risk factors for coronary artery disease. <i>International Journal of Impotence Research</i> , 2005 , 17 Suppl 1, S7-S11	2.3	3
181	The effects of sildenafil on ocular blood flow. 2005 , 83, 355-9		34
180	Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. 2005 , 95, 36-42		51
179	Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease. 2005 , 95, 327-31		13
178	Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). 2005 , 96, 313-21		216
177	Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. 2005 , 96, 37M-41M		36
176	Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. 2005 , 96, 47M-51M		150
175	Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). 2005 , 96, 85M-93M		99
174	Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2005 , 2, 407-14	1.1	15
173	Effects of sildenafil on major arterial blood flow using duplex sonography. 2005 , 33, 173-5		3

172	Hemodynamic effects of sildenafil citrate (Viagra) on segmental branches of bilateral renal arteries. <i>International Urology and Nephrology</i> , 2005 , 37, 785-9	2.3	2
171	Effect of sildenafil citrate on the cardiovascular system. 2005 , 38, 1303-11		8
170	Type 5 phosphodiesterase inhibition: the focus shifts to the heart. <i>Circulation</i> , 2005 , 112, 2589-91	16.7	14
169	Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. <i>Circulation</i> , 2005 , 112, 2642-9	16.7	142
168	Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005 , 1, 283-93	5.5	34
167	Cardiovascular system as a core of sexual life. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2223-30	4	2
166	Sildenafil Citrate, the Classic PDE5 Inhibitor. 2005 , 65-83		4
165	cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. 2005 , 96, 100-9		170
164	Disfunci3 sexual en la hipertensi3 arterial. 2005 , 22, 59-72		4
163	Disfunci3 sexual en la hipertensi3 arterial. 2005 , 22, 59-72		0
162	Oral Pharmacotherapy for Male Sexual Dysfunction. 2005 ,		
161	Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 75-84	4	43
160	Viagra: the risks of recreational use. <i>American Journal of Medicine</i> , 2005 , 118, 569-70	2.4	8
159	Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. <i>Expert Opinion on Drug Safety</i> , 2005 , 4, 531-40	4.1	18
158	Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease. 2005 , 22, 823-44		17
157	Safety and tolerability of oral erectile dysfunction treatments in the elderly. 2005 , 22, 323-38		5
156	Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. 2006 , 20, 722-35		22
155	Evaluation and medical management of erectile dysfunction. 2006 , 81, 385-90		17

154	An overview of the diagnosis and treatment of erectile dysfunction. 2006 , 66, 2339-55		17
153	Oral Therapy for Erectile Dysfunction. 2006 , 271-286		
152	Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis. 2006 , 47, 1471-7		17
151	Effect of regular phosphodiesterase type 5 inhibition in hypertension. 2006 , 48, 622-7		80
150	Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. 2006 , 68, 47-60		55
149	Male Sexual Function. 2006 , 1173-1194		1
148	. 2006 ,		
147	Extranodal Hodgkin disease presenting with gluteal mass and hypercalcemia. <i>Southern Medical Journal</i> , 2006 , 99, 1149-50	0.6	6
146	Iranian medical sciences students participate in science production: publication rate of abstracts presented at Annual Research Meetings of Iranian Medical Sciences Students. <i>Southern Medical Journal</i> , 2006 , 99, 1145-6	0.6	2
145	Cluster of invasive infections, including endocarditis, caused by nontoxigenic <i>Corynebacterium diphtheriae</i> . <i>Southern Medical Journal</i> , 2006 , 99, 1144-5	0.6	2
144	Variations of jugular veins: phylogenic correlation and clinical implications. <i>Southern Medical Journal</i> , 2006 , 99, 1146-7	0.6	2
143	Endovascular treatment of intrahepatic inferior vena cava obstruction from malignant hepatocellular tumor thrombus utilizing Luminex self-expanding nitinol stents. <i>Southern Medical Journal</i> , 2006 , 99, 1148-9	0.6	8
142	Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. 2006 , 17, 493-9		8
141	Stroke--an adverse reaction to sildenafil. 2006 , 29, 165-7		8
140	Endothelial dysfunction: a comprehensive appraisal. 2006 , 5, 4		277
139	Changes in peak systolic velocity induced by chronic therapy with phosphodiesterase type-5 inhibitor. 2006 , 38, 84-6		3
138	Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study. 2006 , 23, 121-8		50
137	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. 2006 , 5, 689-702		366

136	Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. <i>Journal of Sexual Medicine</i> , 2006 , 3, 303-8	1.1	64
135	The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. <i>Journal of Sexual Medicine</i> , 2006 , 3, 28-36; discussion 36	1.1	230
134	[Erectile dysfunction, a new symptom for the cardiologist]. 2006 , 55, 187-91		2
133	Cardioprotection with sildenafil: implications for clinical practice. 2006 , 13, 3155-64		16
132	Cardiovascular effects of phosphodiesterase 5 inhibitors. <i>Current Pharmaceutical Design</i> , 2006 , 12, 3485-94	3.9	45
131	Sex, the heart, and heart failure. 2006 , 10, 256-8		5
130	Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. <i>Heart</i> , 2006 , 92, 170-6	5.1	27
129	Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment. 2006 , 4, 173-80		14
128	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. <i>International Journal of Impotence Research</i> , 2007 , 19, 139-48	2.3	45
127	Chronic sildenafil in men with diabetes and erectile dysfunction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007 , 3, 451-64	5.5	24
126	Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. <i>Circulation</i> , 2007 , 116, 1555-62	16.7	394
125	Antibiotic selection is crucial for optimal empiric monotherapy of ventilator-associated pneumonia. 2007 , 35, 1992-4		1
124	Are nitrates safe in patients who use sildenafil? Maybe. 2007 , 35, 1988-90		5
123	Electric impedance tomography, the final frontier is close: the bedside reality. 2007 , 35, 1996-7		4
122	Higher volume isn't always better. 2007 , 35, 1982-3		
121	The costs of prolonged mechanical ventilation: how much is too much?. 2007 , 35, 1994		1
120	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. 2007 , 15, 76-86		52
119	Neurogenic pulmonary edema: another multiple-hit model of acute lung injury. 2007 , 35, 1979-80		11

118	Moving beyond assessment: without a goal, how should you know when you failed?. 2007 , 35, 1987-8		0
117	Levosimendan: right for the right ventricle?. 2007 , 35, 1995-6		0
116	Caveats for triple-H therapy in the management of vasospasm after aneurysmal subarachnoid hemorrhage. 2007 , 35, 1985-6		5
115	Carbon monoxide, toxic by-product or protective gaseous monoxide?. 2007 , 35, 1990-1		1
114	Is there an association between hemostatic abnormalities and the outcome of acute lung injury?. 2007 , 35, 1980-2		2
113	Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. 2007 , 35, 1863-8		18
112	Classification of acute kidney injury using RIFLE: What's the purpose?. 2007 , 35, 1983-4		31
111	Acute effects of a single dose of phosphodiesterase type 5 inhibitor (sildenafil) on systemic arterial blood pressure during exercise and 24-hour ambulatory blood pressure monitoring in heart transplant recipients. 2007 , 39, 3142-9		12
110	Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. <i>Circulation</i> , 2007 , 116, 238-48	16.7	420
109	Diabetic Neuropathy. 2007 ,		7
108	[Acute myocardial infarction associated to the Sildenafil consumption. A case report and review of the literature]. 2007 , 31, 52-7		1
107	Type 5 phosphodiesterase inhibition in heart failure: the next step. 2007 , 50, 2145-7		14
106	Long-term use of sildenafil in the therapeutic management of heart failure. 2007 , 50, 2136-44		256
105	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. <i>International Journal of Impotence Research</i> , 2007 , 19, 281-95	2.3	33
104	Helping the failing heart and penis. 2007 , 61, 716-8		
103	Effect of sildenafil citrate (Viagra) on coronary flow in normal subjects. 2008 , 25, 72-6		3
102	Evolving Strategies in ED Management: Focus on a Novel Dosing Regimen. <i>Journal of Sexual Medicine</i> , 2007 , 4, 53-58	1.1	
101	[Novel indications for phosphodiesterase type 5 inhibitors]. 2007 , 102, 617-30		4

100	Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. <i>Cardiovascular Drugs and Therapy</i> , 2007 , 21, 171-94	3.9	61
99	Phosphodiesterase 5 inhibition in essential hypertension. <i>Current Hypertension Reports</i> , 2008 , 10, 52-7	4.7	27
98	Failure is an option: learning from unsuccessful proof-of-concept trials. 2008 , 13, 913-6		26
97	An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents. <i>Journal of Sexual Medicine</i> , 2008 , 5, 2405-13	1.1	5
96	The cardiovascular safety of tadalafil. <i>Expert Opinion on Drug Safety</i> , 2008 , 7, 43-52	4.1	8
95	Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. <i>European Respiratory Journal</i> , 2008 , 31, 759-64	13.6	100
94	Immediate- and late-hemodynamic coronary effects of tadalafil in men with erectile dysfunction and coronary artery disease. <i>International Journal of Impotence Research</i> , 2008 , 20, 168-72	2.3	1
93	Evaluation of the effects of sildenafil citrate (viagra) on vertebral artery blood flow in patients with vertebro-basilar insufficiency. <i>Korean Journal of Radiology</i> , 2008 , 9, 477-80	6.9	5
92	PDE5 inhibitors in non-urological conditions. <i>Current Pharmaceutical Design</i> , 2009 , 15, 3521-39	3.3	24
91	Cardiovascular effects of phosphodiesterase type 5 inhibitors. <i>Journal of Sexual Medicine</i> , 2009 , 6, 658-74	4.1	38
90	Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. <i>Diabetes/Metabolism Research and Reviews</i> , 2009 , 25, 136-43	7.5	17
89	Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. <i>Acta Pharmacologica Sinica</i> , 2009 , 30, 1-24	8	45
88	Induction of PDE5 and de-sensitization to endogenous NO signaling in a systemic resistance artery under altered blood flow. <i>Journal of Molecular and Cellular Cardiology</i> , 2009 , 47, 57-65	5.8	11
87	[Erectile dysfunction in the cardiovascular patient]. <i>Medicina Clínica</i> , 2009 , 132, 309-10	1	
86	Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. <i>American Journal of Lifestyle Medicine</i> , 2009 , 3, 201-211	1.9	1
85	Phosphodiesterase 5 inhibitors: are they cardioprotective?. <i>Cardiovascular Research</i> , 2009 , 83, 204-12	9.9	29
84	Pharmacotherapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2010 , 7, 524-40	1.1	132
83	Cardiovascular aspects of sexual medicine. <i>Journal of Sexual Medicine</i> , 2010 , 7, 1608-26	1.1	80

82	Pulmonary hypertension in heart failure. <i>Journal of Cardiac Failure</i> , 2010 , 16, 461-74	3.3	63
81	A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension. <i>Circulation Journal</i> , 2011 , 75, 677-82	2.9	17
80	Stopwatch-assessed duration of erection: a new measure of the efficacy of erectile dysfunction treatments. <i>International Journal of Impotence Research</i> , 2011 , 23, 9-16	2.3	5
79	Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in men. <i>Journal of Mens Health</i> , 2011 , 8, 109-118	1.2	2
78	Effect of phosphodiesterase type 5 inhibition on microvascular coronary dysfunction in women: a Women's Ischemia Syndrome Evaluation (WISE) ancillary study. <i>Clinical Cardiology</i> , 2011 , 34, 483-7	3.3	34
77	Pulmonary hypertension in heart failure with preserved ejection fraction: a target for therapy?. <i>Circulation</i> , 2011 , 124, 133-5	16.7	8
76	Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects. <i>Hormone and Metabolic Research</i> , 2012 , 44, 766-75	3.1	22
75	Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. <i>Circulation</i> , 2012 , 125, 2353-62	16.7	47
74	Abordaje multidisciplinar en el paciente cardiovascular: papel de la Andrología. <i>Revista Internacional De Andrología</i> , 2012 , 10, 21-27	0.6	
73	The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 644-9	2.3	22
72	Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. <i>Current Hypertension Reports</i> , 2013 , 15, 475-83	4.7	42
71	Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions. <i>American Journal of Medicine</i> , 2013 , 126, 192-9	2.4	25
70	Impotence. 2013 , 379-388		
69	Phosphodiesterase 5 inhibition-induced coronary vasodilation is reduced after myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013 , 304, H1370-81	5.2	16
68	Acute effects of sildenafil and dobutamine in the hypertrophic and failing right heart in vivo. <i>Pulmonary Circulation</i> , 2013 , 3, 599-610	2.7	6
67	Sildenafil increases sympathetically mediated vascular tone in humans. <i>American Journal of Hypertension</i> , 2013 , 26, 762-9	2.3	12
66	Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. <i>BMC Medicine</i> , 2014 , 12, 185	11.4	58
65	Perspectives: Coronary microvascular dysfunction in post-infarct remodelled myocardium. <i>European Heart Journal Supplements</i> , 2014 , 16, A74-A79	1.5	4

64	Short term effects of sildenafil citrate therapy in secondary pulmonary hypertension. <i>Egyptian Heart Journal</i> , 2014 , 66, 49-53	1.3	4
63	A systematic review of the association between erectile dysfunction and cardiovascular disease. <i>European Urology</i> , 2014 , 65, 968-78	10.2	267
62	Understanding of chest pain in microvascular disease proved by cardiac magnetic resonance image (UMPIRE): study protocol for a randomized controlled trial. <i>Trials</i> , 2014 , 15, 333	2.8	6
61	Effects of the recreational use of PDE5 inhibitors on the corpus cavernosum of young, healthy rats. <i>International Urology and Nephrology</i> , 2014 , 46, 1889-93	2.3	2
60	Acute coronary syndrome and sildenafil--coincidence or coexistence. <i>American Journal of Emergency Medicine</i> , 2014 , 32, 178	2.9	
59	Acute effect of sildenafil on myocardial ischemic territories in patients with stable coronary artery disease. <i>Egyptian Heart Journal</i> , 2014 , 66, 43-48	1.3	0
58	Acute coronary syndrome and sildenafil - coincidence or coexistence: author reply. <i>American Journal of Emergency Medicine</i> , 2014 , 32, 178-9	2.9	
57	Sexual Dysfunction in Men and Women. 2016 , 785-830		1
56	Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2281-2289	4	1
55	Type 2 Diabetes. 2016 ,		2
54	Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 183-192	5.5	19
53	Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?. <i>Heart</i> , 2018 , 104, 1244-1250	5.1	43
52	Phenolic analysis and erectogenic function of African Walnut (<i>Tetracarpidium conophorum</i>) seeds: The impact of the seed shell on biological activity. <i>Journal of Food Biochemistry</i> , 2019 , 43, e12815	3.3	6
51	Video-based assessment of drug-induced effects on contractile motion properties using human induced pluripotent stem cell-derived cardiomyocytes. <i>Journal of Pharmacological and Toxicological Methods</i> , 2020 , 105, 106893	1.7	2
50	Combined Intravenous Sildenafil and L-Arginine Administration in a Porcine Animal Model: Hemodynamic Safety Profile and Effects on Coronary Blood Flow. <i>Drugs in R and D</i> , 2020 , 20, 279-290	3.4	
49	Sildenafil citrate in healthy and diseased hearts. <i>Journal of Cardiology and Cardiovascular Medicine</i> , 2021 , 6, 033-039	0.1	0
48	Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition. 2004 , 207-237		1
47	Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. 2004 , 139-161		1

46	Genitourinary Complications. 2007 , 453-472		2
45	Sexual Dysfunction in Men and Women. 2011 , 778-816		2
44	Aortic dissection after sildenafil-induced erection. <i>Southern Medical Journal</i> , 2006 , 99, 1151-2	0.6	13
43	Phosphodiesterase 5. 2006 ,		8
42	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	1
41	Pharmaka mit Wirkung auf die NO-Signaltransduktion. 2001 , 21-35		
40	Der NO/cGMP-Signaltransduktionsweg. 2001 , 5-7		
39	Einleitung. 2001 , 1-3		
38	Körperliches Training und Endothelfunktion. 2001 , 17-19		
37	Psychosoziale Probleme. 2001 , 387-399		
36	Mechanismen potenziell vasoprotektiver Wirkungen von NO. 2001 , 9-16		
35	Therapie. 2002 , 129-246		
34	Management of impotence in diabetes. 2002 , 69-107		
33	Metabolic and Toxic Encephalopathies. 2003 , 991-1009		1
32	Sildenafil citrate: a 5-year update on the worldwide treatment of 20 million men with erectile dysfunction. 2004 , 35-47		
31	Safety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery Disease. 2004 , 179-194		
30	Erectile Dysfunction. 2004 , 213-223		
29	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. 2004 , 159-181		

28 Sexual Activity As a Trigger of Myocardial Infarction/Ischemia. **2004**, 251-260

27 Cardiovascular safety of sildenafil in the treatment of erectile dysfunction. **2004**, 151-162

26 Sildenafil Citrate and the Nitric Oxide/Cyclic Guanosine Monophosphate Signaling Pathway. **2004**, 89-116

25 Oral Type 5 Phosphodiesterase Therapy for Male and Female Sexual Dysfunction. **2004**, 107-119

24 Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases. **2004**, 129-142

23 Sildenafil, pharmacology of a highly selective PDE5 inhibitor. **2004**, 15-33

2

22 References. **2004**, 56-58

21 Erectile Dysfunction Assessment and Management in Primary Care Practice. **2005**, 149-183

20 Erectile Dysfunction and the Heart. **2006**, 367-373

19 Phosphodiesterase Inhibitors. **2007**, 20-23

18 Erectile Dysfunction and Cardiovascular Disease. **2007**, 2791-2801

17 Section V: Treatment of Sexual Dysfunction in Patients with Special Problems. **2007**, 459-478

16 Erectile dysfunction. **2007**, 503-513

15 Diabetic Peripheral Neuropathy and Sexual Dysfunction. **2007**, 277-312

14 Uremic and Dialysis Encephalopathies. **2009**, 201-234

13 Impotence. **2009**, 385-393

12 Erectile Dysfunction. **2009**, 519-526

11 Phosphodiesterase-5 Inhibitors in Cardioprotection. **2013**, 439-458

10 Cardiac Issues Related to Erectile Dysfunction. **2006**, 61-75

9 Sildenafil: from the bench to the bedside. *Cmaj*, **2000**, 163, 1171-5 3.5 6

8 Four-year review of sildenafil citrate. *Reviews in Urology*, **2002**, 4 Suppl 3, S26-38 1 9

7 Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage. *Reviews in Urology*, **2003**, 5 Suppl 7, S21-7 1 7

6 Pharmacotherapy of sexual dysfunctions : current status. *Indian Journal of Psychiatry*, **2004**, 46, 213-20 2.2 5

5 Pharmacological developments in antihypertensive treatment through nitric oxide-cGMP modulation. *Advances in Pharmacology*, **2022**, 5.7 1

4 Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. *Science Translational Medicine*, **2022**, 14, 17.5 1

3 The NO / cGMP / PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders. 1

2 Alterations in endothelial nitric oxide synthase activity and their relevance to blood pressure. **2022**, 205, 115256 0

1 The efficacy of PDE5 inhibitors in diabetic patients. 2